RxDoctor Payments Data

Brittany Kubena, PA

Physician Assistant · Alice, TXNPI 1992004998

Payments from drug & device makers

$468in general payments, 2019–2025

Across 29 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$100
  • Takeda Pharmaceuticals U.S.A., Inc.$75
  • Lilly USA, LLC$50
  • Astellas Pharma US Inc$47
  • Amarin Pharma, Inc.$39
  • AstraZeneca$38
  • plus $119 from 7 others

What the payments were for

  • Food & beverage$468100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$468 in reported general payments places this provider in the 50th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$35,197
Medicare patients
125
Services billed
695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide103$134,615
JardianceEmpagliflozin119$108,410
MounjaroTirzepatide75$80,951
OzempicSemaglutide62$67,765
EliquisApixaban74$52,790
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$28,134
JanuviaSitagliptin Phosphate27$25,466
FarxigaDapagliflozin Propanediol35$23,324
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$17,341
Tresiba Flextouch U-200Insulin Degludec12$13,747
RybelsusSemaglutide14$13,169
TradjentaLinagliptin16$12,407
LinzessLinaclotide19$12,100
VascepaIcosapent Ethyl20$10,822
Lagevrio (Eua)Molnupiravir15$8,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$50$215,567178 claims
Novo NordiskOzempic, Rybelsus$100$80,93476 claims
GSKTrelegy Ellipta, Breo Ellipta$16$32,77747 claims
AstraZenecaFarxiga, Symbicort$38$26,16147 claims
AbbVieLinzess$19$12,10019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Alice

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →